Two months after the vaccine was approved, Pfizer disclosed its 2021 revenue guidance for the first time on Tuesday.Pfizer expects that the BNT162b2 new coronary pneumonia vaccine developed in cooperation with BioNTech will generate $15 billion in revenue this year, accounting for about 25% of its expected total revenue, and said that this number may rise further as more agreements are signed.
At the same time, Pfizer raised its profit forecast for 2021 and expects adjusted diluted earnings per share to be between 3.1 and 3.2 US dollars, higher than the initial estimate of 3 to 3.1 US dollars.Pfizer said,BNT162b2The adjusted pre-tax profit is expected to exceed40Billion dollars, the profit margin is20%the above,As vaccine prices rise and costs fall, profits may increase further.
Pfizer CEO Albert Bourla said,The “increasingly likely situation” is that people need to strengthen injections or more different vaccine formulations to deal with new variant viruses, which will bring a “lasting” income stream.
If this is an open market, which means that doctors and citizens have the ability to choose the vaccines they want to receive, we will have a huge market share.
The latest research shows that some new coronavirus variants can evade the defense mechanism of existing vaccines, thereby weakening or even ineffective vaccines. The official website of the authoritative scientific journal Nature reported that against the new coronavirus variant 501Y.V2 from South Africa, the defense effect of the existing new coronavirus vaccine may be weaker than previously expected, and the virus may re-infect people who have previously been infected with the new coronavirus.
Pfizer said in late January that it is actively preparing to adjust the vaccine formula to deal with possible more complicated virus variants. It takes about 6 weeks to adjust the vaccine formula to deal with the new strain. However, the specific time to market depends on the government regulatory agency, which will determine what experimental data proves the vaccine is true and effective, and whether further clinical trials are required.
As the first vaccine approved for emergency use in the United States, as of January 31, Pfizer has delivered 29 million doses of two-dose vaccine to the US government. According to the US Centers for Disease Control and Prevention (CDC), as of this Monday, 17 million vaccine doses have been distributed. Globally, Pfizer said it has provided 65 million doses of vaccine.
Pfizer said on Tuesday that it plans to deliver 200 million doses of the new crown vaccine to the United States by May, ahead of its initial forecast in July. He also said that by the end of this year, 2 billion doses of vaccine are expected to be delivered worldwide.
Pfizer also announced its fourth-quarter and full-year 2020 financial reports, showing that its fourth-quarter revenue was US$11.684 billion, an increase of 12% year-on-year; net profit was US$594 million and a net loss of US$337 million in the same period last year. Among them, the revenue from BNT162b2 was 154 million U.S. dollars, which was lower than market expectations of 684.1 million U.S. dollars.
On Tuesday, Pfizer’s shares fell 2.26% as of the close of US stocks, to $34.99.